Epithelioid Inflammatory Myofibroblastic Sarcoma Responsive to Surgery and an ALK Inhibitor in a Patient with Panhypopituitarism
-
- Kurihara-Hosokawa Kotomi
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Kawasaki Isao
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Tamai Anna
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Yoshida Yoko
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Yakushiji Yosuke
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Ueno Hiroki
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Fukumoto Mariko
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
-
- Fukushima Hiroko
- Department of Pathology, Osaka City General Hospital, Japan
-
- Inoue Takeshi
- Department of Pathology, Osaka City General Hospital, Japan
-
- Hosoi Masayuki
- Department of Metabolism and Endocrinology, Osaka City General Hospital, Japan
この論文をさがす
抄録
We encountered a case of epithelioid inflammatory myofibroblastic sarcoma (EIMS) originating from an abdominal organ that rapidly regrew twice. The patient underwent two surgeries. Large tumors grew within three months after the second surgery. The patient subsequently received chemotherapy with an anaplastic lymphoma kinase (ALK) inhibitor. Although EIMS has a poor prognosis, the patient continues to be alive with disease 14 months after surgical treatment and the administration of the ALK inhibitor.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 53 (19), 2211-2214, 2014
一般社団法人 日本内科学会